HCW Biologics Inc. filings document a clinical-stage biopharmaceutical issuer developing fusion immunotherapeutics through the TOBI and TRBC platforms. Its SEC records include 8-K reports for operating results, clinical and regulatory program updates, material agreements, licensing activity and Nasdaq-related corporate events, along with registration statements covering securities offerings and related capital-structure disclosures.
HCWB proxy and governance filings describe annual meeting matters, shareholder voting procedures and bylaw amendments, including quorum provisions. The company’s formal disclosures also address product-candidate development, financial condition, emerging growth company status, risk factors, ownership and governance controls relevant to its public-company reporting profile.
HCW Biologics Inc. ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 353,680 shares of Common Stock, representing 4.99% of the class. The filing states Armistice Capital exercises shared voting and dispositive power over these shares through its role as investment manager. The filing is signed May 15, 2026.
HCW Biologics Inc. reported a sharp turnaround for the three months ended March 31, 2026, driven by a major licensing deal. Net revenues rose to $6,531,930 from $1,013 a year earlier, largely from a Trimmune license that generated $6.5 million of revenue.
The company moved from a net loss of $2,196,875 to net income of $3,472,480, with net income attributable to common stockholders of $1,984,008, or $0.37 per share. Total assets increased to $27,342,213, including an investment in Trimmune and Wugen.
Despite the profitable quarter, management discloses cumulative net losses of $102.3 million, low cash of $1,228,879, ongoing legal and debt obligations, and explicitly states that these factors raise substantial doubt about the company’s ability to continue as a going concern for at least 12 months.
HCW Biologics Inc. reported a sharp turnaround for the three months ended March 31, 2026, driven by a major licensing deal. Net revenues rose to $6,531,930 from $1,013 a year earlier, largely from a Trimmune license that generated $6.5 million of revenue.
The company moved from a net loss of $2,196,875 to net income of $3,472,480, with net income attributable to common stockholders of $1,984,008, or $0.37 per share. Total assets increased to $27,342,213, including an investment in Trimmune and Wugen.
Despite the profitable quarter, management discloses cumulative net losses of $102.3 million, low cash of $1,228,879, ongoing legal and debt obligations, and explicitly states that these factors raise substantial doubt about the company’s ability to continue as a going concern for at least 12 months.
HCW Biologics reported first quarter 2026 results showing a sharp swing to profitability driven by a new licensing deal. Revenue for the three months ended March 31, 2026 rose to $6.54 million from $5,065 a year earlier, largely from an exclusive worldwide license for HCW11-006 with Trimmune that generated a $3.5 million cash fee and a $3.5 million equity interest. Net income for the quarter improved to $3.47 million from a loss of $2.20 million, while net income attributable to common stockholders was $1.98 million, or $0.37 per share. Despite the stronger quarter, the company states there is “substantial doubt” about its ability to continue as a going concern over the next 12 months without additional funding, and it is appealing a Nasdaq decision to delist its shares for failing to meet the $1.00 minimum bid price requirement.
HCW Biologics reported first quarter 2026 results showing a sharp swing to profitability driven by a new licensing deal. Revenue for the three months ended March 31, 2026 rose to $6.54 million from $5,065 a year earlier, largely from an exclusive worldwide license for HCW11-006 with Trimmune that generated a $3.5 million cash fee and a $3.5 million equity interest. Net income for the quarter improved to $3.47 million from a loss of $2.20 million, while net income attributable to common stockholders was $1.98 million, or $0.37 per share. Despite the stronger quarter, the company states there is “substantial doubt” about its ability to continue as a going concern over the next 12 months without additional funding, and it is appealing a Nasdaq decision to delist its shares for failing to meet the $1.00 minimum bid price requirement.
HCW Biologics Inc. filed a Post-Effective Amendment to its Form S-1 to extend the offering termination date and to update the prospectus for an offering of up to 18,181,818 shares of Common Stock (or pre-funded warrants) for gross proceeds of up to $5,600,000.
The company states the offering is being conducted on a reasonable best efforts basis, with an assumed reference price of $0.308 per share and estimated net proceeds of approximately $5.1 million if all shares are sold (assuming no pre-funded warrants). Proceeds are intended to fund clinical and preclinical development, including trials for HCW9302, R&D, business development, patent work and general corporate purposes.
The prospectus discloses Nasdaq compliance history: a Panel hearing was held on May 5, 2026 regarding a minimum bid-price deficiency and the company awaits the Panel’s determination. The registration statement states no additional securities are being registered in this amendment and that certain directors and officers intend to purchase an aggregate of $430,000 of the offered securities on the same terms as other investors.
HCW Biologics Inc. reported that its April 27, 2026 Special Meeting of Stockholders was adjourned without any business because there was no quorum. The two proposals scheduled for that meeting will instead be voted on at the virtual Annual Meeting on June 15, 2026, with an April 22, 2026 record date.
The company is asking stockholders to approve warrants issued to Armistice Capital Master Fund Ltd. to purchase up to 5,497,702 shares of common stock at $0.6055 per share. Armistice has invested $17.4 million in HCW Biologics. The company is required to seek stockholder approval every 60 days until it is obtained, which means it will continue to incur costs for additional voting efforts.
HCW Biologics Inc. plans to enter two consulting agreements that will begin only if a planned public offering on Form S-1 closes. The company expects both agreements to start on or about May 1, 2026 after the financing close.
HCW Biologics agreed to engage I.R. Agency LLC as a marketing consultant for future marketing efforts, with fees of $2.5 million to be paid from the public offering proceeds. It also agreed to engage Bowery Consulting Group as a financial consultant for six months, with a $500,000 fee, also payable from the same offering proceeds.
HCW Biologics Inc. is asking stockholders to approve several governance and capital structure actions at its June 15, 2026 virtual annual meeting. Key items include electing two Class II directors, ratifying Crowe LLP as auditor for 2026, and authorizing a reverse stock split between 1-for-5 and 1-for-20 to help maintain Nasdaq listing after a bid-price deficiency notice.
Stockholders are also asked to approve issuance of up to 2,477,292 shares upon exercise of Common Warrants and the repricing and share issuance upon exercise of 3,020,410 Existing Warrants at an adjusted exercise price of $0.6055, both tied to prior financings with Armistice Capital and Nasdaq Listing Rule 5635(d). The bylaws quorum threshold has been reduced to 33 1/3% of voting power to facilitate holding meetings.
HCW Biologics Inc. is registering up to 13,625,304 shares of common stock, or the same number of pre-funded warrants plus 13,625,304 underlying shares, in a reasonable best efforts public offering targeting gross proceeds of about $5.6 million. The assumed price is $0.411 per share, matching the April 20, 2026 Nasdaq close. Shares outstanding would rise from 6,734,104 to 20,359,408 if only stock is sold, creating substantial dilution; management estimates new investors would see about $0.08 per-share dilution at the assumed price. Net proceeds of roughly $5.2 million are expected to fund clinical development of lead programs such as HCW9302, research and development, business development and general corporate purposes. The deal has no minimum, so the company may receive significantly less if fewer securities are sold. The company is currently working to address Nasdaq bid-price compliance through a May 5, 2026 hearing while remaining an emerging growth and smaller reporting company.